Efficacy of olmesartan medoxomil (OLM) at 2- (Sankyo Pharma GmbH 2002) and 8- (Puchler et al 2001) weeks in a pooled analysis of 7 placebo-controlle-dtrials: primary efficacy endpoints.
a) The proportion of patients achieving a target sitting systolic blood pressure ≤140 mmHg
b) The proportion of patients achieving a target sitting dystolic blood pressure (DBP) of ≤90 mmHg.
c) Mean change from baseline in sitting DBP.
Note: *p<0.001